12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revlimid lenalidomide regulatory update

FDA said it will update the label of Celgene's Revlimid lenalidomide to include a warning that the drug is associated with an increased risk of developing new cancers in newly diagnosed multiple myeloma (MM) patients, specifically acute myelogenous leukemia (AML), myelodysplastic...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >